Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

ClinicalTrials.gov ID: NCT01225172

Public ClinicalTrials.gov record NCT01225172. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Hormone Receptor-Positive Breast Cancer Subjects With Acquired Resistance to Non-Steroidal Aromatase Inhibitors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate oral doses of BMS-754807 in combination with letrozole or BMS-754807 alone are safe and efficacious in locally advanced or metastatic hormone receptor positive breast cancer subjects who have progressed with prior non-steroidal aromatase inhibitor treatment.

Study identification

NCT ID
NCT01225172
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
77 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 30, 2010
Primary completion
Nov 29, 2014
Completion
Nov 29, 2014
Last update posted
Aug 10, 2020

2010 – 2014

United States locations

U.S. sites
21
U.S. states
12
U.S. cities
17
Facility City State ZIP Site status
Univ Of Al At Birmingham Birmingham Alabama 35294
Mayo Clinic Arizona Scottsdale Arizona 85259
Sharp Clinical Oncology Research San Diego California 92123
Mayo Clinic Jacksonville Florida 32224
University Of Chicago Medical Center Chicago Illinois 60637
Illinois Cancercare, Pc Peoria Illinois 61615
Indiana University Health Goshen Center For Cancer Care Goshen Indiana 46526
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Baltimore Maryland 21231-1000
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins Baltimore Maryland 21231
Oncology Care Associates, P.A. Wheaton Maryland 20902
Masonic Cancer Ctr, University Of Minnesota Minneapolis Minnesota 55455
Mayo Clinic Rochester Minnesota 55905
Unv. Of Nc At Chapel Hill Chapel Hill North Carolina 27599-7305
Unv. Of Nc At Chapel Hill Chapel Hill North Carolina 27599
Presbyterian Hospital Cancer Research Charlotte North Carolina 28204
Duke University Medical Center-Dept Of Medicine Durham North Carolina 27710
Ut Md Anderson Can Ctr. Houston Texas 77030-4009
Ut Md Anderson Can Ctr. Houston Texas 77030
University Of Virginia Health System Charlottesville Virginia 22908
University Of Wisconsin Madison Wisconsin 53792-6164
University Of Wisconsin Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01225172, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 10, 2020 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01225172 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →